No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
SRPT240726C148000
- 2.40
- -1.00-29.41%
15min DelayClose Jul 19 16:00 ET
2.40High2.40Low
2.40Open3.40Pre Close1 Volume3 Open Interest148.00Strike Price240.00Turnover50.40%IV3.29%PremiumJul 26, 2024Expiry Date0.00Intrinsic Value100Multiplier4DDays to Expiry2.40Extrinsic Value100Contract SizeAmericanOptions Type0.4053Delta0.0459Gamma61.31Leverage Ratio-0.3643Theta0.0075Rho24.85Eff Leverage0.0650Vega
Intraday
- 5D
- Daily
News
Wall Street Analysts Believe Sarepta Therapeutics (SRPT) Could Rally 38.04%: Here's Is How to Trade
Here's How Much $1000 Invested In Sarepta Therapeutics 10 Years Ago Would Be Worth Today
Sarepta Therapeutics (NASDAQ:SRPT) has outperformed the market over the past 10 years by 10.36% on an annualized basis producing an average annual return of 21.14%. Currently, Sarepta Therapeutics
Buy Rating Affirmed for Sarepta Therapeutics Amid Strong Elevidys Demand and Strategic Growth Outlook
Jim Cramer Says Don't Sell Match Group: 'You've Just Got A Very, Very Smart Investor In There'
On CNBC's "Mad Money Lightning Round," Jim Cramer said Fortinet, Inc. (NASDAQ:FTNT) is not his favorite. He added that we own Palo Alto Networks, Inc. (NASDAQ:PANW) for the charitable trust.On July 11
Express News | Cassava Sciences Inc: Renewal of Quarterly Analyst Calls
Express News | Cassava Sciences Inc: Ongoing Phase 3 Trials Are Being Run According to FDA and Industry Standards
Comments
$Fortinet(FTNT.US$ : “I think Fortinet is not my favorite. Palo Alto is, we own it for the Charitable Trust.”
$Air Products & Chemicals(APD.US$ : “You really don’t want to be in Air Products, you want to be in Linde. Linde’s a much better run company, and that’s why Air Products isn’t doing as well , and Linde’s doing spectacularly.”
$Sarepta Therapeutics(SRPT.US$ : “I think Sarepta is a speculative situation where they have great science. ...
$Air Products & Chemicals(APD.US$ : “You really don’t want to be in Air Products, you want to be in Linde. Linde’s a much better run company, and that’s why Air Products isn’t doing as well , and Linde’s doing spectacularly.”
$Sarepta Therapeutics(SRPT.US$ : “I think Sarepta is a speculative situation where they have great science. ...
1
1
Jinta Hong, CFA
Background
As we enter the second half of 2024, the global financial landscape remains dynamic, influenced by international relations and economic policies. While major markets like the US, Japan, India, and parts of Europe have seen significant growth, Australia has faced challenges such as inflation and weak Chinese economic performance. The $S&P/ASX 200(.XJO.AU$ index reached a historic peak in April ...
Background
As we enter the second half of 2024, the global financial landscape remains dynamic, influenced by international relations and economic policies. While major markets like the US, Japan, India, and parts of Europe have seen significant growth, Australia has faced challenges such as inflation and weak Chinese economic performance. The $S&P/ASX 200(.XJO.AU$ index reached a historic peak in April ...
+7
82
7
🔥 3 PDUFA decisions this week! 👇
📌 This week’s PDUFAs:
$Merck & Co(MRK.US$ : 🤔
⇨ Patritumab deruxtecan
‣ Non-small cell lung carcinoma
‣ PDUFA date: 6/26/24 (BLA)
$Verona Pharma(VRNA.US$ : 🤔
⇨ Ensifentrine (Nebulized)
‣ Chronic obstructive pulmonary disease
‣ PDUFA date: 6/26/24 (NDA)
$Genmab(GMAB.US$ : 🤔
⇨ EPKINLY® (Epcoritamab)
‣ Follicular lymphoma
‣ PDUFA date: 6/28/24 (sBLA)
🗓️ Last week’s PDUFAs:
$Merck & Co(MRK.US$ : Approved 6/17 🎉
⇨ CAPVAXIVE (V116)
‣ Pneumo...
📌 This week’s PDUFAs:
$Merck & Co(MRK.US$ : 🤔
⇨ Patritumab deruxtecan
‣ Non-small cell lung carcinoma
‣ PDUFA date: 6/26/24 (BLA)
$Verona Pharma(VRNA.US$ : 🤔
⇨ Ensifentrine (Nebulized)
‣ Chronic obstructive pulmonary disease
‣ PDUFA date: 6/26/24 (NDA)
$Genmab(GMAB.US$ : 🤔
⇨ EPKINLY® (Epcoritamab)
‣ Follicular lymphoma
‣ PDUFA date: 6/28/24 (sBLA)
🗓️ Last week’s PDUFAs:
$Merck & Co(MRK.US$ : Approved 6/17 🎉
⇨ CAPVAXIVE (V116)
‣ Pneumo...
9
by Luzi Ann Santos | moomoo News
U.S. stock indices retreated as Nvidia gave back some of its recent gains ahead of the quarter-end rebalancing of investors' portfolio that could further drive volatility.
The $S&P 500 Index(.SPX.US$ slipped 0.2% to 5464.62, while the $Nasdaq Composite Index(.IXIC.US$ fell 0.2% to 17689.36 . The $Dow Jones Industrial Average(.DJI.US$ managed to hold on to gains, even as it cl...
U.S. stock indices retreated as Nvidia gave back some of its recent gains ahead of the quarter-end rebalancing of investors' portfolio that could further drive volatility.
The $S&P 500 Index(.SPX.US$ slipped 0.2% to 5464.62, while the $Nasdaq Composite Index(.IXIC.US$ fell 0.2% to 17689.36 . The $Dow Jones Industrial Average(.DJI.US$ managed to hold on to gains, even as it cl...
48
10
Stocks inched mostly higher at midday Friday, with the $S&P 500 Index(.SPX.US$ and $Nasdaq Composite Index(.IXIC.US$ trading close to Thursday's record intraday highs as market favorite $NVIDIA(NVDA.US$continued to set the tone for trading.
The S&P 500 gained 3.44 points (0.1%) to trade at 5,476.51 shortly before 12:30 p.m. ET Friday – slightly below the 5,505.53 intraday record that it briefly hit on Thursday befo...
The S&P 500 gained 3.44 points (0.1%) to trade at 5,476.51 shortly before 12:30 p.m. ET Friday – slightly below the 5,505.53 intraday record that it briefly hit on Thursday befo...
7
1
Read more
LELT : In practice co diversity the security risk. This preclude Fortinet and Fortinet has solid FS